Antibodies undergo genomic recombination and somatic hypermutation in order to obtain their high levels of both antigen specificity and affinity. These very mechanisms by which the adaptive immune system is able to generate antibodies against any antigen also lead to molecular issues as therapeutic candidates. Large-scale data capture in LabKey Biologics of sequence, cellular expression, purification, efficacy, biophysical characterization, and atomic-level characterization will enable methods development to better predict and repair molecular attributes such as post-translational modifications and stability. Pushing this level of molecular design earlier in the therapeutic pathway will help lower the cost of biologics-based therapeutics.
